Skip to main content

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Written by Customer Service on . Posted in Mergers And Acquisitions.

Acquisition expands Cellution Biologics’ human tissue-based portfolio and marks its entry into the U.S. reconstructive surgery market

ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) — Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).

The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive surgery market, adding a new surgical category to its existing portfolio across wound care, ocular repair and other surgical applications. SimpliDerm is an established human acellular dermal matrix with a proven commercial presence in the U.S. reconstructive surgery market.

The acquisition also provides Cellution with established relationships across the U.S. reconstructive surgery market, including surgeons, hospitals, GPOs and IDNs.

“The acquisition of SimpliDerm marks an important step in Cellution Biologics’ strategy to expand our human tissue-based portfolio and strengthen our capabilities across surgical markets. By bringing SimpliDerm into our portfolio, we are combining an established U.S. reconstructive surgery business with Cellution’s expertise in tissue processing, manufacturing and quality. 

We look forward to building on this foundation and creating greater value for our healthcare partners and the patients they serve,” said Shiva Arjunon, President, Cellution Biologics Inc.

Expanding Cellution Biologics’ Reconstructive Surgery Portfolio

The acquisition brings SimpliDerm’s established U.S. reconstructive surgery business together with Cellution Biologics’ expertise in human tissue processing, manufacturing and commercialization. By combining these capabilities, Cellution Biologics aims to build on the existing SimpliDerm business while supporting its continued development within the Company’s broader surgical portfolio.

Transaction Details

Under the terms of the transaction, Cellution Biologics acquired the SimpliDerm business for US$8 million payable at closing, subject to agreed adjustments, together with up to US$3 million in additional transition and commercial milestone payments over the next 18 months, subject to the terms of the definitive agreement.

About SimpliDerm

SimpliDerm is a hydrated human acellular dermal matrix (hADM) designed for use in surgical applications including soft tissue repair and reconstruction. The portfolio is available in a range of configurations and sizes to support different surgical needs.

About Cellution Biologics Inc.

Cellution Biologics is focused on developing, manufacturing and commercializing advanced human tissue-based products for wound care, ocular repair, reconstructive surgery and other surgical applications. Through expertise in tissue processing, manufacturing and quality systems, the Company is committed to advancing high-quality tissue-based solutions designed to address evolving clinical needs and support healthcare professionals across diverse surgical settings.

Media Contact

Jon Werner
VP – Marketing
Cellution Biologics
jon.w@cellutionbiologics.com
+1-443-315-3344

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.